Table 6.
Associations between HLA and Graves’ orbitopathy in Caucasian population.
| First author | Ref. | Year | Population | Method | No. of GO patients | No. of GD patients | Nr of healthy controls | High risk HLA | Protective HLA |
|---|---|---|---|---|---|---|---|---|---|
| Farid | (66) | 1980 | Canadian | serological | 24 | 53 | – | DR3 | NR |
| Frecker M | (94) | 1986 | Hungarian | serological | 52 | 55 | – | Genotypes B8-DR3 B8-DR7 |
DR7 without B8 |
| Schifferdecker E | (75) | 1991 | German | Serological | 84 | 26 | – | No significant correlation | No significant correlation |
| Boehm BO | (80) | 1992 | German | SSOP | 72 | 100 | 223 | Heterozygotes DRB3*01:01/*02:02 |
NR |
| Badenhoop K | (95) | 1996 | German | SSOP | 135 | 124 | 229 | significance of DQA1*05:01 not confirmed | NR |
| Kendall-Taylor P | (72) | 1988 | British | serological | 60 | 67 | 500 | none | none |
| Frecker M | (96) | 1988 | Canadian | serological | 64 | 69 | 140 | B8 DR7 DR3 |
DR4 |
| Weetman AP | (97) | 1988 | British | RFLP DR3only |
53 | 51 | 90 | significance of DR3 not confirmed | NR |
| Villanueva R | (98) | 2000 | American | SSP | 61 | 40 | 121 | none | none |
| Yin X | (99) | 2012 | American | RFLP DR3 only |
156 | 90 | – | significance of DR3 not confirmed | NR |
| Stasiak M | (15) | 2023 | Polish | NGS | 70 | 91 | 2217 |
A*01:01
A*32:01 B*37:01 B*39:01 B*42:01 C*08:02 C*03:02 DRB1*03:01 DRB1*14:01 DQB1*02:01 |
C*04:01
C*03:04 C*07:02 DRB1*15:02 |
RFLP, restriction fragment length polymorphism, SSOP, sequence specific oligonucleotide probe; SSP, sequence specific primers; NGS, next generation sequencing; NR, not reported; -, no control group included.